Business Context and Reporting Period
This Form 6-K filing by DBV Technologies S.A. covers the month of September 2017. The company is a biotechnology firm developing Viaskin, a proprietary epicutaneous immunotherapy (EPIT) platform for treating food allergies and other immune diseases. The filing primarily serves to announce management participation in upcoming investor conferences.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a press release regarding corporate events and does not contain financial statements or performance data.
Material Changes
No material financial or operational changes versus a prior comparable period are reported in this filing. The document focuses solely on scheduled investor relations activities.
Guidance, Outlook, and Management Commentary
Management has scheduled presentations at two major investor conferences in September 2017:
- Citi's 12th Annual Biotech Conference: Charles Ruban (Chief Commercial Officer) and Susanna Mesa (SVP, Strategy) will host investor meetings in Boston on September 7, 2017.
- Morgan Stanley 15th Annual Global Healthcare Conference: David Schilansky (COO & Deputy CEO) and Susanna Mesa will present in New York on September 12, 2017. A live webcast and replay will be available on the company website.
The company continues clinical trials for Viaskin Peanut and Viaskin Milk, preclinical development for Viaskin Egg, and a proof-of-concept study for Viaskin Milk in treating Eosinophilic Esophagitis.
Key Facts for Investor Verification
- Verify the dates and times of the upcoming presentations at the Citi and Morgan Stanley conferences.
- Confirm the availability of the live webcast and replay for the Morgan Stanley presentation on the company's Investor Relations website.
- Note that this filing contains no financial data; investors should refer to the most recent Form 20-F or quarterly reports for financial performance.
- Review the status of ongoing clinical trials for Viaskin Peanut and Viaskin Milk in subsequent filings.